Shionogi Inc. (U.S.) company information, Employees & Contact Information

Enrollment Update Shionogi Inc.

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections The AI Journal

Gareth Morgan Named President of Qpex Biopharma, Inc. FinancialContent

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients 2 Minute Medicine

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek Business Wire

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan The AI Journal

Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library | Shionogi & Co., Ltd. Shionogi Inc.

FDA will review ensitrelvir for COVID-19 prevention Healio

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative

Receives U.S. FDA Fast Track Designation for the Novel Anti-Respiratory Syncytial Virus Drug Candidate S-337395 UBE株式会社

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations Business Wire

Tadashi Hara Shionogi Inc.

History Shionogi Inc.

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬 Shionogi Inc.

Message from Top Management Shionogi Inc.

Improving affordability for patients in need | Access to healthcare | Shionogi & Co., Ltd. Shionogi Inc.

Nathan McCutcheon Shionogi Inc.

Improving access to healthcare services in developing countries Shionogi Inc.

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats Business Wire

Shionogi Appoints Dr. Ramón Polo as Senior Vice President citybiz

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections Business Wire

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals GSK

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone CalMatters

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir ACS Publications

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine NEC Global

Fetroja Approved for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia Medical Professionals Reference

Novel COVID-19 Antiviral Ensitrelvir Provides Earlier Symptom Relief in Phase 3 Trial Infectious Disease Advisor

The Leadership Connection BOSS Publishing

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S‑217622 Business Wire

Ensitrelvir reduces household spread of SARS-CoV-2, study shows Healio

Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S. Business Wire

Development of an automatable highly sensitive method for coronavirus detection in wastewater (COPMAN method) EurekAlert!

Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore PR Newswire

Fetroja Approved for Complicated UTI in Patients With Limited or No Alternative Tx Options Medical Professionals Reference

“Gamma Wave Sound” jointly developed by Pixie Dust Technologies, Inc. and Shionogi & Co., Ltd. won the ACC TOKYO CREATIVITY AWARDS for Creative Innovation Gold and ICC Summit Award Pixie Dust Technologies

“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care. Business Wire

AutoPhagyGO, Curations, and Dentsu Advance to the Semifinals of the XPRIZE Healthspan Competition dentsu.co.jp

Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 PR Newswire

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease Medical Professionals Reference

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic® GlobeNewswire

Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena® From Shionogi Inc. PR Newswire

Duchesnay Expands its Women's Health Product Portfolio with Acquisition of Osphena® from Shionogi Inc. PR Newswire Canada

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million Via Ritzau